about
Clinical Pharmacokinetics of MetforminLong-term patterns of online evidence retrieval use in general practice: a 12-month studyEffects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazideEffect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsManipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]Recent developments in targeting access to high cost medicines in Australia.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study GroupTargeted pharmacotherapy of evoked phenomena in neuropathic pain: a review of the current evidenceEffects of two commercial electronic prescribing systems on prescribing error rates in hospital in-patients: a before and after studyErrors and electronic prescribing: a controlled laboratory study to examine task complexity and interruption effects.Audit and feedback of antibiotic use: utilising electronic prescription data.Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations.Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.Protocol for the Quick Clinical study: a randomised controlled trial to assess the impact of an online evidence retrieval system on decision-making in general practiceA double-blind, placebo-controlled study of the short term effects of a spring water supplemented with magnesium bicarbonate on acid/base balance, bone metabolism and cardiovascular risk factors in postmenopausal womenPACE--the first placebo controlled trial of paracetamol for acute low back pain: design of a randomised controlled trialLearning from hackers: open-source clinical trials.Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects.Formoterol, a highly β2-selective agonist, increases energy expenditure and fat utilisation in men.The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model.Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens.Tolerability of paracetamol.Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).A proposal for identifying the low renal uric acid clearance phenotypePharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial.A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?The management of severe hypertension in Australian general practiceCareTrack Australia: assessing the appropriateness of adult healthcare: protocol for a retrospective medical record review.The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicinesHuman subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques.Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsTies that bind: multiple relationships between clinical researchers and the pharmaceutical industry.The pharmacokinetics of oxypurinol in people with gout.The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in AustraliaFailure to utilize functions of an electronic prescribing system and the subsequent generation of 'technically preventable' computerized alerts.Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients.
P50
Q22241422-35579D00-F04C-4E2E-815F-729B825434FAQ24288625-6611D764-159C-4563-975E-E3E5A96A71E8Q24651117-44D35AF0-39FC-4900-97DF-5EF0811C5158Q24678775-46442C3E-6B8B-4A29-BFA0-ECBC9610F693Q24814118-EC6D1DE7-7B14-4A0E-9B78-CCC3AA3063E7Q25254962-72EFECB2-B34F-42CD-960B-26D07AE427F4Q28138338-03C855F9-D10B-4525-8911-7B73398FA18FQ28284585-BBF5AC0B-6637-421D-8935-E8B3A12C2703Q28480437-91E756D2-00C3-405D-AEF9-2E65561BE772Q30497527-74AC3D67-4C86-4E34-8B3B-CD4A9BF8E523Q30740426-9A1290A7-D4A0-4CB8-8F0A-C42484E9902DQ31160745-CD8F9E82-C08D-4E2F-B717-C2AFD78E4617Q33248583-9041C32C-9598-477F-B97C-2C6A72F3D993Q33255011-CD5B32E7-40AA-4B47-B972-9C6D683BE9ACQ33616927-7B6193D7-79B4-46A3-9D01-643854FC9257Q33637931-CA73F5B5-82AC-480D-8135-FDBA5DC25181Q33761499-98159B98-E829-4EAB-A065-F4DCDFB7C36AQ33795072-01D23BCA-1EDD-49D3-9975-22CA32FEF170Q34277747-35F8DCB7-6C07-465F-ABFD-AF68E6AB1BD9Q34347558-118D4B9C-0C14-4EB1-A68A-68181FB8A750Q34372885-6234B481-2E6E-4F40-B142-BA510AAC15B4Q34396147-237F3729-67A6-4253-8E1D-015CA72467BEQ34397956-3BCF240F-77AA-4B19-8C13-2287F9D5F791Q34587063-57715A85-3235-4B88-91B4-C2213695AE36Q34595377-206E52B8-6ED9-46FC-B8BD-6B0DB56864BEQ34613990-EA34BB08-166F-4B20-B4A2-A13076C34443Q34626715-B56D4F33-7462-47CE-AE3C-DF56FC493603Q34656225-E2FDB515-D11E-4A9D-949A-FBF883FAC158Q34712231-FDE4340E-3296-40E5-BBD2-61B8FFFA19A7Q34797671-3598827E-4BDD-4A23-83AC-E62B6C63FDC3Q35016105-9EC99AFD-1B04-4052-8DD7-1067E366333BQ35687005-89E91342-8787-4EAE-9F4A-502D713D0EA4Q35688491-DDF432EF-9F18-4FB8-B0BD-DA953496B6B6Q35825795-693FF0C2-6BF4-4665-9E6F-D9A9DA5AAC1AQ35826093-1B495040-A7E6-4D09-B556-CF55FA3629AAQ36325458-A38F6C83-E17C-46FD-B200-846A9DCEAD81Q36336035-9CAD37FE-B59F-49DA-8D27-A878B049564EQ36440050-72354D94-0FB2-405A-8EB0-1E95FCD0E398Q36500446-F8F789D6-F000-415A-ADCB-CE6CAEF03DD4Q36633418-B9A7627F-DDE5-4106-9988-ED044236E040
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Richard Day
@ast
Richard Day
@en
Richard Day
@es
Richard Day
@nl
Richard Day
@sl
type
label
Richard Day
@ast
Richard Day
@en
Richard Day
@es
Richard Day
@nl
Richard Day
@sl
altLabel
Ric Day
@en
prefLabel
Richard Day
@ast
Richard Day
@en
Richard Day
@es
Richard Day
@nl
Richard Day
@sl
P1006
P214
P244
P1006
P1053
D-8699-2011
P106
P1153
55445642800
7402616845
P1960
n87lOUQAAAAJ
P21
P214
P244
P31
P3829
P496
0000-0002-6045-6937
P734
P735
P7859
lccn-n85375420